Quantum Biopharma (QNTM) Competitors $17.15 -2.01 (-10.49%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$17.45 +0.30 (+1.75%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock QNTM vs. LIMN, CADL, PVLA, DBVT, SGMT, IMMP, ACB, NGNE, TVRD, and BTMDShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Liminatus Pharma (LIMN), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), DBV Technologies (DBVT), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Aurora Cannabis (ACB), Neurogene (NGNE), Tvardi Therapeutics (TVRD), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Quantum Biopharma vs. Its Competitors Liminatus Pharma Candel Therapeutics Palvella Therapeutics DBV Technologies Sagimet Biosciences Prima BioMed Aurora Cannabis Neurogene Tvardi Therapeutics biote Quantum Biopharma (NASDAQ:QNTM) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do institutionals and insiders believe in QNTM or LIMN? 1.2% of Quantum Biopharma shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, QNTM or LIMN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$14.20M-$15.98-1.07Liminatus PharmaN/AN/AN/AN/AN/A Does the media refer more to QNTM or LIMN? In the previous week, Quantum Biopharma and Quantum Biopharma both had 1 articles in the media. Quantum Biopharma's average media sentiment score of 0.41 beat Liminatus Pharma's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liminatus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is QNTM or LIMN more profitable? Liminatus Pharma's return on equity of 0.00% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -155.20% -94.90% Liminatus Pharma N/A N/A N/A SummaryQuantum Biopharma beats Liminatus Pharma on 3 of the 5 factors compared between the two stocks. Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.60M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-1.0721.5627.6620.25Price / SalesN/A283.36423.00177.43Price / CashN/A42.7336.8958.10Price / Book3.787.518.035.67Net Income-$14.20M-$55.14M$3.18B$249.21M7 Day Performance-21.04%4.61%2.93%3.28%1 Month Performance11.00%0.90%1.72%3.95%1 Year PerformanceN/A5.40%34.39%20.98% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum BiopharmaN/A$17.15-10.5%N/AN/A$49.60MN/A-1.07N/ALIMNLiminatus PharmaN/A$11.15+17.6%N/AN/A$246.62MN/A0.00N/AGap UpCADLCandel Therapeutics2.4754 of 5 stars$5.06+3.3%$22.00+334.8%-12.4%$245.50M$120K-3.7860Analyst RevisionPVLAPalvella Therapeutics3.4491 of 5 stars$22.54+2.1%$46.29+105.3%N/A$244.11M$42.81M-1.86N/ADBVTDBV Technologies3.7508 of 5 stars$9.16+3.2%$14.75+61.0%+175.1%$243.22M$4.15M-1.8680Analyst UpgradeGap UpSGMTSagimet Biosciences2.3894 of 5 stars$7.62-3.2%$26.60+249.1%+175.2%$241.41M$2M-4.338IMMPPrima BioMed0.9777 of 5 stars$1.64flat$7.00+326.8%-11.9%$239.50M$5.14M0.002,021Positive NewsACBAurora Cannabis0.1849 of 5 stars$4.24+2.2%N/A-5.1%$233.29M$246.72M38.551,130NGNENeurogene3.8137 of 5 stars$14.95-7.5%$46.17+208.8%-41.3%$230.48M$930K-3.4490News CoverageTVRDTvardi TherapeuticsN/A$23.33-5.2%$71.50+206.5%N/A$230.37M$7.14M0.0080BTMDbiote3.1004 of 5 stars$4.02-4.3%$8.00+99.0%-43.0%$229.78M$197.19M6.59194News CoveragePositive News Related Companies and Tools Related Companies Liminatus Pharma Alternatives Candel Therapeutics Alternatives Palvella Therapeutics Alternatives DBV Technologies Alternatives Sagimet Biosciences Alternatives Prima BioMed Alternatives Aurora Cannabis Alternatives Neurogene Alternatives Tvardi Therapeutics Alternatives biote Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNTM) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNTM Stock Alerts